President & Representative Director, Towa Pharmaceutical Co.,Ltd.
Other assets (est.): the sum of each year's after-tax income (pay + dividends in own name − estimated taxes and social insurance) dividends retained by asset-management companies (less about 20% corporate tax), and proceeds from share sales (the drop in shares from the previous year × share price, less 20.315% tax, or about 30% for asset-management companies), for the years we have data. Spending, real estate, donations and savings from earlier years are not reflected.
Asset-management companies: Yoshida Office Co., Ltd.est., Yoshida Estate Ltd.est. (their holdings are included in net worth)
| Company | Held by | Shares | Stake | Price | Value | Dividends |
|---|---|---|---|---|---|---|
| Towa Pharmaceutical Co.,Ltd. 4553 · FY ending Mar 2026 |
Yoshida Office Co., Ltd. | 20,100,000 | 40.83% | ¥4,005 | ¥80.5B | ¥1.6B |
| Towa Pharmaceutical Co.,Ltd. 4553 · FY ending Mar 2026 · President & Representative Director |
Own name | 1,455,300 | 2.96% | ¥4,005 | ¥5.8B | ¥116M |
| Towa Pharmaceutical Co.,Ltd. 4553 · FY ending Mar 2026 |
Yoshida Estate Ltd. | 648,000 | 1.32% | ¥4,005 | ¥2.6B | ¥51.8M |
| Year | Net worth | Pay | Dividends | Total income | Taxes (est.) | After tax (est.) | Share sales (after tax) |
|---|---|---|---|---|---|---|---|
| 2026 | ¥88.9B | ¥36.8M | ¥1.8B | ¥1.8B | ¥71.0M | ¥80.2M | — |
| 2025 | ¥59.5B | ¥113M | ¥1.6B | ¥1.7B | ¥106M | ¥106M | — |
| 2024 | ¥64.5B | ¥38.2M | ¥1.3B | ¥1.4B | ¥57.5M | ¥66.1M | — |
Grouped by the calendar year of each company's fiscal year-end. Years in which the person was not among the top 10 shareholders of a company exclude that company.